Arachnoiditis Treatment Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2027

Arachnoiditis Treatment Market: Introduction

Arachnoid is a thin and transparent membrane, also known as meninges, which protects the nerves of the spinal cord. Inflammation of the arachnoid results in a pain disorder, which leads to arachnoiditis. The inflammation occurs due to irritation from spine injury, chemicals, infections, compression in the spinal nerves, or post spine surgical complications. The inflammation results into scar tissue and adhesions, which cause nerves to stick together and cause arachnoiditis. Symptoms of arachnoiditis include numbness, tingling, burning pain in lower legs, and this rare condition causes paralysis in the legs in some people.

View Report : https://www.transparencymarketresearch.com/arachnoiditis-treatment-market.html

Arachnoiditis causes severe and chronic pain, and neurological deficits, and the symptoms vary from mild to severe. The pattern of the condition is unpredictable; however, it depends on symptoms, severity, and progression. Age and mild neurological symptoms could worsen arachnoiditis and result in paralysis. Arachnoiditis is quite common in people aged between 40 and 60. It is a rare condition and the risk factors include diabetes, alcoholism, AIDS, chemotherapy, and organ transplantation. Prevalence of arachnoiditis is low; however, an estimated 25,000 cases occur every year in North & South America, Asia, and Europe.

Key Drivers and Restraints of Global Arachnoiditis Treatment Market

Rise in number of spinal surgeries, increase in incidence of bacterial & viral spinal infections, surge in pain relief procedures, awareness & understanding about arachnoiditis, and adoption of novel treatments are the major drivers of the global arachnoiditis treatment market. Moreover, increase in the geriatric population is a major factor propelling the global arachnoiditis treatment market. Technological advancements and awareness about proper diagnosis are likely to augment the global arachnoiditis treatment market. Adoption of various diagnostic tools such as inflammatory markers and magnetic resonance imaging (MRI) are likely to drive the global market.
Initiatives taken by governments and various organizations to spread awareness about arachnoiditis are also anticipated to boost the growth of the global arachnoiditis treatment market. For instance, the State of Michigan declared Arachnoiditis Awareness Month every year, with a goal of creating maximum awareness about the disease and its treatment. These factors are projected to fuel the growth of the global arachnoiditis treatment market. Strong research & development, increase in diagnosis rate, and technological advancements are the other drivers of the global market.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76649

North America to Lead Global Arachnoiditis Treatment Market

In terms of region, the global arachnoiditis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America is projected to dominate the global arachnoiditis treatment market during the forecast period owing to higher prevalence of arachnoiditis, rise in spinal surgeries, and increase in minimally invasive procedures. Rise in risk of bacterial & viral infections, pre- and post-surgical complications, and increase in the geriatric population are the factors anticipated to drive the arachnoiditis treatment market in North America. Moreover, rise in initiatives to spread awareness about this rare disease condition is likely to drive the need of diagnostic tools. This factor is projected to propel the arachnoiditis treatment market in the region. Supportive health care expenditure, government initiatives, and demand for better treatment are factors anticipated to augment the market in North America. Europe was the second largest market for arachnoiditis treatments in 2018, followed by Asia Pacific. Rise in number of spine surgeries, increase in the geriatric population, and continuous investments in research & development are the factors boosting the growth of the arachnoiditis treatment market in Europe.
Asia Pacific is anticipated to be the fastest growing market for arachnoiditis treatments in the next few years. This is attributed to increase in minimal invasive surgeries, awareness and adoption of treatments for arachnoiditis, and improvement in the health care system. Increase in diagnostic tools, availability of pain relief medications, ongoing studies on surgery as a treatment, and developing infrastructure are likely to boost the growth of the arachnoiditis treatment market in the region.

REQUEST FOR COVID19 IMPACT ANALYSIS – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76649

Key Players Operating in Global Arachnoiditis Treatment Market

The global arachnoiditis treatment market is fragmented, with the presence of a number of large and small players. Major players in the global arachnoiditis treatment market are:

Baxter
B. Braun Melsungen AG
Pfizer, Inc.
AstraZeneca
Bristol-Myers Squibb Company
Sandoz International GmbH
Takeda Pharmaceutical Company Limited
Novartis AG
Others

Global Arachnoiditis Treatment Market: Research Scope

Global Arachnoiditis Treatment Market, by Disease Type

Adhesive Arachnoiditis
Arachnoiditis Ossificans
Cerebral Arachnoiditis
Hereditary Arachnoiditis
Neoplastic Arachnoiditis
Optochiasmatic Arachnoiditis

Global Arachnoiditis Treatment Market, by Treatment

Drug Class

Neuropathic Agents
Opioids
Analgesics
Adrenergic Agents

Physical Therapy
Nerve Stimulation
Others

Global Arachnoiditis Treatment Market, by End-user

Hospitals
Clinics
Ambulatory Surgical Centers
Others

Global Arachnoiditis Treatment Market, by Region

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain
Rest of Europe

Asia Pacific

China
India
Japan
Australia & New Zealand
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East & Africa

GCC Countries
South Africa
Rest of Middle East & Africa

2. https://www.biospace.com/article/cholesterol-lowering-drugs-market-increase-in-prevalence-of-coronary-artery-disease-to-drive-market/